Scientists to inject migraine patients with protein to spark aura attacks
NCT ID NCT07342296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will give 21 people with migraine with aura an infusion of a protein called PACAP-38, or a placebo, to see if it can trigger an aura attack. The goal is to better understand what causes migraine aura, not to test a treatment. Participants will be monitored for 12 hours after the infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PACAP-38 (a protein given as an IV infusion)
What this could lead to
If it works, this could help researchers understand what causes migraine aura, potentially pointing toward new treatments.
What could go wrong
This is a very small, early study with only 21 people. It is designed to trigger symptoms, not to treat them, so there is no direct benefit to participants. Results may not apply to all migraine patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE WITH AURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••